STUDY OF THE BCL-2 INHIBITOR VENETOCLAX IN COMBINATION WITH STANDARD INTENSIVE ACUTE MYELOID LEUKEMIA (AML) INDUCTION/CONSOLIDATION THERAPY WITH FLAG-IDA IN PATIENTS WITH NEWLY DIAGNOSED OR RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA (AML):